Assessment of Quality of Life and Psychological Problems in Patients With Multiple Sclerosis
NCT ID: NCT05029830
Last Updated: 2023-02-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
70 participants
OBSERVATIONAL
2021-09-01
2022-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
2. To study effect of psychiatric comorbidity on the disease activity by using clinical, laboratory and psychiometric tools.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cortical Inhibition in Patients With Multiple Sclerosis
NCT07128160
Demographics, Clinical and Paraclinical Characteristics of Multiple Sclerosis in Egypt
NCT02970370
Enhancing Quality of Life in MS Patients Through Tailored Therapeutic Education
NCT06450600
Sexual Dysfunction in Patients With Relapsing Remitting Multiple Sclerosis and Associated Comorbidities
NCT04157283
Multiple Sclerosis Versus Neuromyelitis Optica Spectrum Disorder
NCT07304960
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
MS etiology is not yet fully understood. However, it is considered a multifactorial disease with environmental and genetic variables being risk factors with immunological implications that alter myelin (white matter) . Myelin, when degraded due to the inflammatory process inherent to the disease (flare-up), can lead to scarring (plaques/lesions) which, in turn, leads to a CNS impairment in the transmission of impulses, resulting in complications in the functioning of several organs.
The impact of MS on patients' quality of life (QoL) is undeniable. However, there are other variables whose influence are significant, such as duration of diagnosis that is associated with worse physical and mental QoL, the degree of disability, and the evolution of the disease, which also appear to be negatively associated with QoL.
Recent studies have attempted to correlate advancing neurologic disability with impaired QOL in MS patients . However, advancing neurologic disability has been shown to only partly explain impaired QOL . This supports the hypothesis that factors other than neurologic disability play a role in the QOL of MS patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
investigations like MRI..
• Multiple Sclerosis Quality of Life-54 (MSQOL-54) Can be considered as the most known disease-specific instrument for the evaluation of quality of life in patients with multiple sclerosis (MS). It was developed to combine generic quality of life aspects of the SF-36 with MS-targeted dimensions and ratings for the overall quality of life. Therefore, 18 disease-specific items were added to the original 36 items of the SF-36. The 54 items are divided into 12 multi-item and 2 single-item scales. The MSQOL-54 items are transformed linearly to 0-100 scores and final scores are obtained by averaging items within the scales
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. patients aged 18 to 40 years of age.
3. Males and females are included.
4. All patients who received diagnosis of multiple sclerosis whether under treatment or not.
Exclusion Criteria
18 Years
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Samah Ramadan
resident
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shady safwat, lecturer
Role: STUDY_DIRECTOR
Assiut University
gellan karm, lecturer
Role: STUDY_DIRECTOR
Assiut University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Samah
Asyut, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: clinical aspects. Curr Opin Neurol. 2018 Dec;31(6):752-759. doi: 10.1097/WCO.0000000000000622.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.